National Bank of Canada
CERE

National Bank of Canada’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

National Bank of Canada’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-9
Closed -$372 – 3105
2024
Q2 		$372 Hold
9
– – ﹤0.01% 2579
2024
Q1 		$379 Buy
+9
New +$378 ﹤0.01% 2612

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

National Bank of Canada's CERE Position: Q3 2024 in Review

National Bank of Canada sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 9 shares — an estimated $372 sold.

National Bank of Canada first reported a position in CERE in Q1 2024 and held it in 2 quarters. The position peaked at $379 in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • National Bank of Canada reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • National Bank of Canada sold 9 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $372.
  • National Bank of Canada first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2024 and held it in 2 quarters.
  • National Bank of Canada's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $379 in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on National Bank of Canada's 13F filing for Q3 2024, filed 12 Nov 2024.